Skip to main content

Intensive Meditation Intervention Aids Schizophrenia Symptoms

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 14, 2024.

By Lori Solomon HealthDay Reporter

WEDNESDAY, Feb. 14, 2024 -- An intensive meditation-based intervention (iMI) significantly improves positive symptoms, particularly refractory hallucinations and delusions, in male patients with schizophrenia, according to a study published online Feb. 6 in Psychiatry and Clinical Neurosciences.

Ting Xue, Ph.D., from the Shanghai Mental Health Center at Shanghai Jiao Tong University, and colleagues investigated the impact of an eight-month daily guided iMI on persistent hallucinations/delusions and health-related quality of life in 64 male inpatients with schizophrenia with treatment-refractory hallucinations and delusions.

The researchers found that iMI significantly reduced Positive and Negative Syndrome Scale total scores and improved positive symptoms and hallucination/delusion items versus a general rehabilitation program at both three and eight months. At eight months, treatment response rates (≥25 percent reduction) for these measures significantly increased in the iMI group. Additionally, iMI significantly increased scores in physical activity and mindfulness skills at both time points compared with general rehabilitation, with a more pronounced effect observed at eight months.

"The findings support iMI as a promising adjunctive therapy alongside antipsychotic medications, particularly for individuals with positive symptoms in clinical settings," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted February 2024

Read this next

AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours

WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...

Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million

TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...

Patient–Primary Care Provider Language Concordance Tied to Better Outcomes

TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.